Important events during the fourth quarter
- Net sales increased by 8% (9% adjusted for currency effects) to
SEK 156 m (144). - The EBITDA margin amounted to 12% (11) or 15% adjusted for items affecting comparability.
Probi launchdProbi ®Sensia , a brand new product concept in mental health.Probi launched two new scientifically proven synbiotic solutions together with Clasado Biosciences at Supply Side West inLas Vegas .-
Per Lindblad took over as CFO on
November 1st . -
The Board of Directors proposed a dividend for the fiscal year 2023 of a total of
SEK 14,8m , corresponding toSEK 1,30 per share.
Important events during the full year 2023
Anita Johansen was appointed CEO.Probi established its own B2C market organization and took over the distribution and sales of theProbi ® brand inSweden .Probi also expanded intoNorway .Probi strengthened its position inNorth America by becoming sole distributor of BLIS K12™ and BLIS M18™ in the US andCanada .Probi launched the spore-forming probiotic Weizmannia coagulans GX-1, aProbi strain with high stability fit for beverages and confectionary type formats.Probi published results of the 3rd clinical study on HEAL9™ in gut-brain area.Probi was granted 23 new patents in 2023.
CEO Comments
Concluding a year of decisive and transformative action
Rounding off my first year leading
Overall, 2023 was a tough year characterized by a general market softness, especially in the North American market. Our sales totaled
By region, the full-year result in
Q4 was largely characterized by "Probi Reinforced", our new strategic direction alongside revised financial targets for 2024-2028. In general, we have put a lot of effort into strengthening our strategy and organizational capabilities for the coming years. These initiatives are expected to start coming into effect by 2025, as 2024 is expected to mainly be a transitional year.
In terms of commercialization, several major events took place in Q4. First, we hosted a 2-day customer workshop in
The initial feedback from our customers has been very positive. Sales cycles to implement new ingredients into our customers brands however are long, and our teams will continue supporting these key launches with activities throughout 2024.
Additionally, several changes were made to reinforce the organization over the year. During Q4 we further strengthened our new management team with CFO Per Lindblad. He has highly relevant financial and business development experience from specialty ingredients industries, including probiotics, and his contributions will be important in further developing our business.
Overall, we have laid a strong foundation and readied the organization for accelerated growth in the coming years. Our focus remains steadfast on innovation, customer focus, and achieving operational excellence on our continued journey. As we now enter a new chapter I am filled with optimism, looking forward to continuing pushing boundaries and pioneering the probiotics market with effective solutions that improve people's health.
CEO
Invitation to teleconference
Contact
Per Lindblad, CFO, Tel: +46 (0)46 286 89 41, E-mail: per.lindblad@probi.com
This information is information that
https://news.cision.com/probi/r/q4-2023--eventful-quarter-caps-transformative-year,c3916013
https://mb.cision.com/Main/1556/3916013/2564245.pdf
(c) 2024 Cision. All rights reserved., source